Page 273 - SAHCS HIVMed Journal Vol 20 No 1 2019

Page 9 of 10 Original Research

Acknowledgements Data availability statement

The authors would like to thank all the patients, all Data sharing is not applicable to this article as no new data
investigators and their teams at the following centres for were created or analysed in this study.
their participation in SALIF: Cameroon: Pascale Abena
Messomo Mbida, Cabinet Medical IDOC, Douala; Roselyne Disclaimer
Toby, Yaoundé Central Hospital, Yaoundé. Kenya: Edwin The views and opinions expressed in this article are those of
Were, Partners in Prevention, Eldoret; Gaudensia Mutua, the authors and do not necessarily reflect the official policy or
KAVI, Kangemi, Nairobi; Gina Ouattara, KAVI, Kenyatta position of any affiliated agency of the authors.
Hospital, Nairobi; Lucas Otieno, Kombewa Clinical Trials
Unit, Nyanza; Reena Shah, Aga Khan University, Nairobi. References
Senegal: Baye Moussa Samba, District Centre de Gaspard
Kamara, Dakar; Kouro Bousso, Centre de Sante Domninique 1. British HIV Association guidelines for the treatment of HIV-1-positive adults with
de Pikine, Pikine. South Africa: Lerato Mohapi, Perinatal antiretroviral therapy 2015 (2016 interim update). August 2016. [cited 2019 Apr 2].
Available from: https://www.bhiva.org/file/RVYKzFwyxpgiI/treatment-guidelines-
HIV Research Unit, Chris Hani Baragwanath Hospital, 2016-interim-update.pdf.
Soweto; Johan Lombaard, Josha Research, Bloemfontein; 2. AIDSinfo. Panel on antiretroviral guidelines for adults and adolescents. Guidelines
for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2018
Rosie Mngqibisa, Enhancing Care Foundation Wentworth [cited 2019 Apr 2] Available from: https://aidsinfo.nih.gov/contentfiles/
lvguidelines/adultandadolescentgl.pdf.
Hospital, Wentworth, Durban; Karla Mellet, University of 3. European AIDS Clinical Society/EACS. EACS guidelines 9.0. October 2017 [cited 2019
the Witwatersrand, Helen Joseph Hospital, Themba Lethu Apr 2] Available from: http://www.eacsociety.org/files/guidelines_9.0-english.pdf.
Research Centre, Johannesburg; Gita Ramjee, HIV Prevention 4. World Health Organization. Updated recommendations on first-line and second-
line antiretroviral regimens and post-exposure prophylaxis and recommendations
Research Unit, Medical Research Council, Westville, on early infant diagnosis of HIV. July 2018. [cited 2019 Apr 2] Available from:
KwaZulu-Natal. Uganda: Paula Munderi, MRC/UVRI http://apps.who.int/iris/bitstream/handle/10665/273632/WHO-CDS-HIV-18.18-
eng.pdf?ua=1.
Uganda Research Unit on AIDS, Entebbe; Andrew Kambugu, 5. Hoffmann C, Wolf E, Schewe K, et al. CNS Toxicity of dolutegravir is not associated
Infectious Diseases Institute, Mulago Hospital Complex, with psychiatric conditions or higher plasma exposure. Abstract 424, presented
at: Conference on Retroviruses and Opportunistic Infections; 2018 Mar 4–7;
Kampala; Cissy Kityo, Joint Clinical Research Centre, Boston, MA. Boston, MA: CROI Foundation/IAS–USA; 2018.
Kampala; Fred Collins Semitala, Makerere University Joint 6. Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two
background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-
AIDS Program, Kampala; Francis Kiweewa, Makerere naive adults infected with HIV-1 (THRIVE): A phase 3, randomised, non-inferiority trial.
Lancet. 2011;378(9787):229–237. https://doi.org/10.1016/S0140-6736(11)60983-5
University Walter Reed Project, Kampala. Thailand: 7. Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and
Anchalee Avihingsanon, HIV-NAT – The Netherlands emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3
randomised double-blind active-controlled trial. Lancet. 2011;378(9787):238–246.
Australia Thailand Research Collaboration, Bangkok; https://doi.org/10.1016/S0140-6736(11)60936-7
Weerawat Manosuthi, Bamrasnaradura Infectious Disease 8. Boehringer Ingelheim. Nevirapine PI: Nevirapine prescribing information. 2016
Institute, Amphur Mueang Nonthaburi; Khuanchai [cited 2019 Mar]. Available from: https://docs.boehringer-ingelheim.com/
Prescribing%20Information/PIs/Viramune/Viramune.pdf
Supparatpinyo, Ries Chiang Mai University Hospital, 9. WHO. WHO Statement on DTG – Geneva 18 May 2018. Potential safety issue
Chiang Mai; Winai Ratanasuwan, Siriraj Hospital affecting women living with HIV using dolutegravir at the time of conception.
2018 [cited 2019 Apr 2]. Available from: https://www.who.int/medicines/
Department of Infectious Disease Faculty of Medicine, publications/drugalerts/Statement_on_DTG_18May_2018final.pdf.
Bangkok. The authors acknowledge Scientific Pathways, 10. Vitoria M, Ford N, Doherty M, Flexner C. Simplification of antiretroviral therapy: A
necessary step in the public health response to HIV/AIDS in resource-limited
part of Nucleus Global, for editorial assistance, funded by settings. Antivir Ther. 2014;19 Suppl 3:31–37. https://doi.org/10.3851/IMP2898
Janssen Pharmaceutica NV. 11. Ford N, Lee J, Andrieux-Meyer I, Calmy A. Safety, efficacy, and pharmacokinetics of
rilpivirine: Systematic review with an emphasis on resource-limited settings. HIV
AIDS (Auckl). 2011;3:35–44. https://doi.org/10.2147/HIV.S14559
Competing interests 12. Janssen Pharmaceutica, N.V. Janssen Global Public Health: HIV medicines access &
partnerships program. 2014. [cited 2019 Apr 2]. Available from: http://
partnerships.ifpma.org/uploads/documents/138_1408024768.pdf.
The authors have declared that no competing interests exist. 13. Domingo P, Ribera E. Data on rilpivirine in treatment-naïve patients. Lessons from
ECHO, THRIVE and STaR. Enferm Infecc Microbiol Clín. 2013;31 Suppl 2:20–29.
https://doi.org/10.1016/S0213-005X(13)70139-3
Authors’ contributions 14. Yagudina R, Kulikov A, Babiy VV. Potential long-term cost savings in treatment of
naïve HIV-infected patients with rilpivirine/tenofovir/emtricitabine (single tablet
All authors reviewed the article and endorsed the data and regimen) in the Russian Federation. Value Health. J Int Soc Pharmacoeconomics
Outcomes Res 2015;18(7):A581. https://doi.org/10.1016/j.jval.2015.09.1941
conclusions. 15. Neogi U, Häggblom A, Singh K, et al. Factors influencing the efficacy of rilpivirine
in HIV-1 subtype C in low- and middle-income countries. J Antimicrob Chemother.
2016;71(2):367–371. https://doi.org/10.1093/jac/dkv359
Funding 16. Gianotti N, Poli A, Nozza S, et al. Efficacy and safety in clinical practice of a
rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically
Marjolein Jansen: employee of Janssen Pharmaceutical suppressed HIV-positive patients on stable antiretroviral therapy. J Int AIDS Soc.
2015;18:20037. https://doi.org/10.7448/IAS.18.1.20037
Companies of Johnson & Johnson and holds stock in 17. Ford N, Calmy A. Improving first-line antiretroviral therapy in resource-limited
Johnson & Johnson. Perry Mohammed: employee of settings. Curr Opin HIV AIDS. 2010;5(1):38–47. https://doi.org/10.1097/
COH.0b013e3283339b41
Janssen Pharmaceutical Companies of Johnson & Johnson 18. EDURANT (rilpivirine) prescribing information. Revised 02/2018. https://www.
and holds stock in Johnson & Johnson. Ceyhun Bicer: accessdata.fda.gov/drugsatfda_docs/label/2018/202022s011lbl.pdf
received consulting fees from Janssen Pharmaceutica NV; 19. Meintjes G, Moorhouse MA, Carmona S, et al. Adult antiretroviral therapy
guidelines 2017. South Afr J HIV Med. 2017;18(1):776. https://doi.org/10.4102/
Yvon van Delft: employee of Janssen Pharmaceutical sajhivmed.v18i1.776
Companies of Johnson & Johnson and holds stock in 20. Manosuthi W, Ongwandee S, Bhakeecheep S, et al. Guidelines for antiretroviral
Johnson & Johnson. therapy in HIV-1 infected adults and adolescents 2014, Thailand. AIDS Res Ther.
2015;12:12. https://doi.org/10.1186/s12981-015-0053-z
http://www.sajhivmed.org.za 266 Open Access